ClinicalTrials.gg
CompletedNCT06107803Updated Mar 26, 2025Results posted

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

A Phase 1 interventional study of Roluperidone 64 mg and Olanzapine 10 MG in Negative Symptoms in Schizophrenia, sponsored by Minerva Neurosciences. Completed at 3 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by Minerva Neurosciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
1,142nd of 1,319
17 · median 66
Started
2023
with 39 others
Phase 1
196 of 1,465
10 open now
Registered
1,336th of 1,465
by date

Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 1,142nd largest by enrollment of the 1,319 interventional ones that give a count, is one of 40 that started in 2023, is one of 196 in phase 1, and was the 1,336th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,465 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of the Co-Administration of Roluperidone and Olanzapine in Adult Subjects with Moderate to Severe Negative Symptoms of Schizophrenia.

The main question this clinical trial aims to answer are the pharmacodynamic and pharmacokinetic effects and safety of the concomitant therapy of Roluperidone with an established and widely used antipsychotic, such as olanzapine in order to provide further guidance to clinical practitioners that may prescribe off-label use of these drugs concomitantly in clinical practice.

Eligible Participants will undergo the following study phases in the clinic:

  • Screening Phase: Between 2 and up to 28 days during which study eligibility will be established and subjects receiving psychotropics will be washed out. Subjects will remain inpatient at the clinical site at least through the end of Treatment Phase 2.
  • Treatment Phase 1: After the Baseline Visit, Roluperidone 64 mg/day will be administered as a monotherapy for 7 days (Days 1-7).
  • Treatment Phase 2: Concomitant administration of Olanzapine 10 mg/day and Roluperidone 64 mg/day for 10 days, starting on Day 8 (Days 8-17). Subjects may be discharged from the clinic at least 48 hours after the last administration of the study drugs and after the collection of the last plasma sample; however, the inpatient period may be extended at the discretion of the investigator.

End of Study (EOS): Will take place at least 14 days after the last dose of the study.

03

Conditions studied

  • Negative Symptoms in Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provided
  • (BMI) \< 35 kg/m2
  • Meets the diagnostic criteria for schizophrenia as defined in the -Fifth Edition (DSM-5), as established by a full psychiatric interview in conjunction with the Mini International Neuropsychiatric Interview (MINI)
  • Documented diagnosis of schizophrenia for at least 1 year before screening
  • Stable in terms of both positive and negative symptoms of schizophrenia over the last 3 months
  • Score of > 20 on the PANSS original negative symptoms subscale (Sum of N1+N2+N3+N4+N5+N6+N7) at Screening and Baseline (Day -1) AND \< 4 points absolute difference between the 2 visits
  • Discontinued psychotropic medications without risk to their clinical status or safety by Baseline
  • Female subject, if not of , must be a woman who is or permanently sterilized
  • Female subject, if of childbearing potential, must test negative for pregnancy and must be using a double barrier method
  • Must be normal metabolizer for P450 CYP 2D6, defined as a subject that has at least one functional allele (eg, *1, *2 or *35), as determined by study-specific genotyping test before the first drug dose is administered
  • Has a caregiver or family member or health care personnel who can provide information towards assessment and support the subject in terms of compliance with the protocol

Exclusion criteria

Exclusion Criteria:

  • Current major depressive disorder, bipolar disorder, panic disorder, obsessive compulsive disorder, or intellectual disability (intellectual developmental disorder diagnosed by age 14)
  • PANSS item score of > 4 on:

    • P4 Excitement/Hyperactivity
    • P6 Suspiciousness/persecution
    • P7 Hostility
    • G8 Uncooperativeness
    • G14 Poor impulse control
  • CDSS total score > 6
  • Score of ≥ 2 on any 2 of items 1, 2, or 3, or a score of ≥ 3 on item 4 of the Barnes Akathisia Rating Scale (BARS)
  • Has had electroconvulsive therapy (ECT), vagal nerve stimulation (VNS), or repetitive trans-cranial magnetic stimulation (r-TMS) within the 6 months prior to the Screening visit or who are scheduled for ECT, VNS, or r-TMS at any time during the study
  • Positive urine drug screen for drugs of abuse
  • Currently taking proton pump inhibitors (PPI)
  • Current systemic infection (eg, , , [HIV], tuberculosis)
  • Requires or may require concomitant treatment with any other medication likely to increase
  • Requires medication inhibiting CYP2D6
  • Safety laboratory results show one or more of the following: potassium \<3.4 mmol/L, or calcium \<2.07 mmol/L, or magnesium \<0.70 mmol/L
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Treatment Phase 1

    Roluperidone 64 mg monotherapy administered as an oral dose daily for 7 days on Days 1-7.

    Drug: Roluperidone 64 mg

  • Experimental
    Treatment Phase 2

    Roluperidone 64 mg oral and olanzapine 10 mg oral administered at the same time daily for 10 days on Days 8-17.

    Drug: Roluperidone 64 mg · Drug: Olanzapine 10 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Extrapyramidal Symptoms Assessed by Abnormal Involuntary Movement Scale (AIMS) - Change From Baseline in AIMS Component Movement

    AIMS is a rating scale to measure tardive dyskinesia (TD). For the scoring, the AIMS scale has 14 items. The first 10 items (under categories of Facial and Oral Movements, Extremity Movements, Trunk Movements, and Global Judgements) are rated from 0 (none) to 4 (severe); the remaining 4 items (Dental Status) are rated "yes" and "no" and not counted. The analysis is limited to items 1 to 10, with each rated from 0 to 4. The total score is the sum of all 10 items and with values ranging from 0 to 40. Overall change from baseline to End of Study (Day 17) in AIMS was reported for the Safety Set. Higher scores imply worse outcome.

    Time frame: Overall - Change from Baseline to End of Study (Day 17)

  2. Barnes Akathisia Rating Scale (BARS)

    BARS is a multiple-choice questionnaire that clinicians may use to provide an assessment of akathisia. The clinician or rater is instructed to observe the subject while standing and while sitting, at least 2 minutes each (total of at least 4 minutes in total). There are 4 areas where the subject is to be evaluated, 1 of these is objective, 2 are subjective, and the final is a global assessment. The BARS scale has 3 items that are rated from 0 (absence/no distress) to 3 (most severe). The BARS rating scale is scored by summing the scales for Objective Akathisia, Subjective Awareness of Restlessness and Subjective Distress Related to Restlessness yielding a total score ranging from 0 to 9. The Total score, which has a possible range from 0-9, is reported. Higher scores imply worse outcome.

    Time frame: Overall - Change from Baseline to End of Study (Day 17)

  3. Number of Subjects Who Experienced Suicidal Ideation or Behavior Events Per the Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a measure to identify and assess individuals at risk for suicide. Questions are phrased for an interview format but can be completed as a self-report measure if needed. It measures 4 constructs: severity of ideation, intensity of ideation, behavior, and lethality. It includes "stem questions," which if endorsed, prompt additional follow-up questions to obtain more information. For the composite endpoint of suicidal ideation or behavior (1-10), the number and percent of subjects in the Overall Safety Set who experience any one of the ten suicidal ideation or behavior events at End of Study (Day 17).

    Time frame: Overall - End of Study (Day 17)

Secondary outcomes

  1. Pharmacokinetic Evaluation of Roluperidone - Maximum Plasma Concentration (Cmax)

    Cmax of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.

    Time frame: Days 1 through 17

  2. Pharmacokinetic Evaluation of Roluperidone - Time to Maximum Plasma Concentration (Tmax)

    Tmax of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.

    Time frame: Days 1 through 17

  3. Pharmacokinetic Evaluation of Roluperidone - Area Under the Plasma Concentration Versus Time Curve (AUC 0-24)

    AUC of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.

    Time frame: Days 1 through 17

  4. Pharmacokinetic Evaluation of Roluperidone - Area Under the Plasma Concentration Versus Time Curve (AUC Inf)

    AUC of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.

    Time frame: Days 1 through 17

  5. Plasma PK Parameter for Olanzapine Cmax

    Cmax of olanzapine administered concomitantly with roluperidone

    Time frame: Treatment Phase 2 (Day 8 through Day 17)

  6. Plasma PK Parameter for Olanzapine Tmax

    Tmax of olanzapine administered concomitantly with roluperidone

    Time frame: Treatment Phase 2 (Day 8 through Day 17)

  7. Plasma PK Parameter for Olanzapine AUC 0-24

    AUC 0-24 olanzapine administered concomitantly with roluperidone

    Time frame: Treatment Phase 2 (Day 8 through Day 17)

  8. Plasma PK Parameter for Olanzapine AUC Inf

    AUC inf olanzapine administered concomitantly with roluperidone

    Time frame: Treatment Phase 2 (Day 8 through Day 17)

  9. Pharmacokinetic Evaluation of Co-administration Versus Roluperidone Monotherapy - Maximum Plasma Concentration (Cmax)

    Comparison of roluperidone on Day 17 with olanzapine to roluperidone alone on Day 7 for Cmax. The geometric mean and geometric coefficient of variation are reported for the analytes roluperidone and its metabolite.

    Time frame: Days 1 through 17

  10. Pharmacokinetic Evaluation of Co-administration - AUC 0-24

    Comparison of roluperidone on Day 17 with olanzapine to roluperidone alone on Day 7 for AUC 0-24. The geometric mean and geometric coefficient of variation are reported for the analytes roluperidone and its metabolite.

    Time frame: Days 1 through 17

07

Results

Posted Mar 26, 2025

Participant flow

Participant flow — Overall Study
MilestoneOverall Safety Set
Started17
Full set17
Safety set17
Pharmacokinetic set12
Pharmacokinetic completer set11
Completed13
Not completed4
Withdrew: Adverse event1
Withdrew: Withdrawal by subject2
Withdrew: Protocol violation1

Outcome measures

PrimaryExtrapyramidal Symptoms Assessed by Abnormal Involuntary Movement Scale (AIMS) - Change From Baseline in AIMS Component Movement

AIMS is a rating scale to measure tardive dyskinesia (TD). For the scoring, the AIMS scale has 14 items. The first 10 items (under categories of Facial and Oral Movements, Extremity Movements, Trunk Movements, and Global Judgements) are rated from 0 (none) to 4 (severe); the remaining 4 items (Dental Status) are rated "yes" and "no" and not counted. The analysis is limited to items 1 to 10, with each rated from 0 to 4. The total score is the sum of all 10 items and with values ranging from 0 to 40. Overall change from baseline to End of Study (Day 17) in AIMS was reported for the Safety Set. Higher scores imply worse outcome.

Time frame:
Overall - Change from Baseline to End of Study (Day 17)
Reported as:
Mean · score on a scale
Extrapyramidal Symptoms Assessed by Abnormal Involuntary Movement Scale (AIMS) - Change From Baseline in AIMS Component Movement
score on a scaleOverall Safety Set
Extrapyramidal Symptoms Assessed by Abnormal Involuntary Movement Scale (AIMS) - Change From Baseline in AIMS Component Movement0.0 ± 0.00
PrimaryBarnes Akathisia Rating Scale (BARS)

BARS is a multiple-choice questionnaire that clinicians may use to provide an assessment of akathisia. The clinician or rater is instructed to observe the subject while standing and while sitting, at least 2 minutes each (total of at least 4 minutes in total). There are 4 areas where the subject is to be evaluated, 1 of these is objective, 2 are subjective, and the final is a global assessment. The BARS scale has 3 items that are rated from 0 (absence/no distress) to 3 (most severe). The BARS rating scale is scored by summing the scales for Objective Akathisia, Subjective Awareness of Restlessness and Subjective Distress Related to Restlessness yielding a total score ranging from 0 to 9. The Total score, which has a possible range from 0-9, is reported. Higher scores imply worse outcome.

Time frame:
Overall - Change from Baseline to End of Study (Day 17)
Reported as:
Mean · score on a scale
Barnes Akathisia Rating Scale (BARS)
score on a scaleOverall Safety Set
Barnes Akathisia Rating Scale (BARS)0.0 ± 0.00
PrimaryNumber of Subjects Who Experienced Suicidal Ideation or Behavior Events Per the Columbia Suicide Severity Rating Scale (C-SSRS)

C-SSRS is a measure to identify and assess individuals at risk for suicide. Questions are phrased for an interview format but can be completed as a self-report measure if needed. It measures 4 constructs: severity of ideation, intensity of ideation, behavior, and lethality. It includes "stem questions," which if endorsed, prompt additional follow-up questions to obtain more information. For the composite endpoint of suicidal ideation or behavior (1-10), the number and percent of subjects in the Overall Safety Set who experience any one of the ten suicidal ideation or behavior events at End of Study (Day 17).

Time frame:
Overall - End of Study (Day 17)
Reported as:
Count of participants · Participants
Number of Subjects Who Experienced Suicidal Ideation or Behavior Events Per the Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsOverall Safety Set
Number of Subjects Who Experienced Suicidal Ideation or Behavior Events Per the Columbia Suicide Severity Rating Scale (C-SSRS)0
SecondaryPharmacokinetic Evaluation of Roluperidone - Maximum Plasma Concentration (Cmax)

Cmax of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.

Time frame:
Days 1 through 17
Reported as:
Mean · ng/ml
Pharmacokinetic Evaluation of Roluperidone - Maximum Plasma Concentration (Cmax)
ng/mlOverall Safety Set - RoluperidoneOverall Safety Set - Metabolite BFB-520
Treatment Phase 1 - Day 132.5 ± 13.75.00 ± 5.69
Treatment Phase 1 - Day 743.6 ± 19.97.98 ± 6.78
Treatment Phase 2 - Day 1767.7 ± 28.612.2 ± 12.9
SecondaryPharmacokinetic Evaluation of Roluperidone - Time to Maximum Plasma Concentration (Tmax)

Tmax of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.

Time frame:
Days 1 through 17
Reported as:
Mean · hr
Pharmacokinetic Evaluation of Roluperidone - Time to Maximum Plasma Concentration (Tmax)
hrOverall Safety Set - RoluperidoneOverall Safety Set - Metabolite BFB-520
Treatment Phase 1 - Day 19.74 ± 7.3716.2 ± 6.72
Treatment Phase 1 - Day 77.47 ± 5.739.60 ± 6.02
Treatment Phase 2 - Day 176.20 ± 4.568.76 ± 4.90
SecondaryPharmacokinetic Evaluation of Roluperidone - Area Under the Plasma Concentration Versus Time Curve (AUC 0-24)

AUC of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.

Time frame:
Days 1 through 17
Reported as:
Mean · hr*ng/mL
Pharmacokinetic Evaluation of Roluperidone - Area Under the Plasma Concentration Versus Time Curve (AUC 0-24)
hr*ng/mLOverall Safety Set - RoluperidoneOverall Safety Set - Metabolite BFB-520
Treatment Phase 1 - Day 1391 ± 25252.3 ± 63.0
Treatment Phase 1 - Day 7507 ± 278135 ± 122
Treatment Phase 2 - Day 17720 ± 321203 ± 225
SecondaryPharmacokinetic Evaluation of Roluperidone - Area Under the Plasma Concentration Versus Time Curve (AUC Inf)

AUC of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.

Time frame:
Days 1 through 17
Reported as:
Mean · hr*ng/mL
Pharmacokinetic Evaluation of Roluperidone - Area Under the Plasma Concentration Versus Time Curve (AUC Inf)
hr*ng/mLOverall Safety Set - RoluperidoneOverall Safety Set - Metabolite BFB-520
Treatment Phase 1 - Day 1338 ± 28960.7 ± 82.0
Treatment Phase 1 - Day 7495 ± 272168 ± 234
Treatment Phase 2 - Day 17883 ± 420263 ± 280
SecondaryPlasma PK Parameter for Olanzapine Cmax

Cmax of olanzapine administered concomitantly with roluperidone

Time frame:
Treatment Phase 2 (Day 8 through Day 17)
Reported as:
Mean · ng/ml
Plasma PK Parameter for Olanzapine Cmax
ng/mlTreatment Phase 2 - Day 17
Plasma PK Parameter for Olanzapine Cmax35.6 ± 12.7
SecondaryPlasma PK Parameter for Olanzapine Tmax

Tmax of olanzapine administered concomitantly with roluperidone

Time frame:
Treatment Phase 2 (Day 8 through Day 17)
Reported as:
Mean · hr
Plasma PK Parameter for Olanzapine Tmax
hrTreatment Phase 2 - Day 17
Plasma PK Parameter for Olanzapine Tmax4.11 ± 2.24
SecondaryPlasma PK Parameter for Olanzapine AUC 0-24

AUC 0-24 olanzapine administered concomitantly with roluperidone

Time frame:
Treatment Phase 2 (Day 8 through Day 17)
Reported as:
Mean · hr*ng/ml
Plasma PK Parameter for Olanzapine AUC 0-24
hr*ng/mlTreatment Phase 2 - Day 17
Plasma PK Parameter for Olanzapine AUC 0-24587 ± 220
SecondaryPlasma PK Parameter for Olanzapine AUC Inf

AUC inf olanzapine administered concomitantly with roluperidone

Time frame:
Treatment Phase 2 (Day 8 through Day 17)
Reported as:
Mean · hr*ng/ml
Plasma PK Parameter for Olanzapine AUC Inf
hr*ng/mlTreatment Phase 2 - Day 17
Plasma PK Parameter for Olanzapine AUC Inf719 ± 144
SecondaryPharmacokinetic Evaluation of Co-administration Versus Roluperidone Monotherapy - Maximum Plasma Concentration (Cmax)

Comparison of roluperidone on Day 17 with olanzapine to roluperidone alone on Day 7 for Cmax. The geometric mean and geometric coefficient of variation are reported for the analytes roluperidone and its metabolite.

Time frame:
Days 1 through 17
Reported as:
Geometric mean · ng/ml
Pharmacokinetic Evaluation of Co-administration Versus Roluperidone Monotherapy - Maximum Plasma Concentration (Cmax)
ng/mlReference - Roluperidone Alone on Day 7Test - Roluperidone With Olanzapine on Day 17
Roluperidone Analyte39.8 ± 46.3762.2 ± 44.78
BFB-520 Analyte5.96 ± 89.128.54 ± 100.10
SecondaryPharmacokinetic Evaluation of Co-administration - AUC 0-24

Comparison of roluperidone on Day 17 with olanzapine to roluperidone alone on Day 7 for AUC 0-24. The geometric mean and geometric coefficient of variation are reported for the analytes roluperidone and its metabolite.

Time frame:
Days 1 through 17
Reported as:
Geometric mean · hr*ng/ml
Pharmacokinetic Evaluation of Co-administration - AUC 0-24
hr*ng/mlReference - Roluperidone Alone on Day 7Test - Roluperidone With Olanzapine on Day 17
Roluperidone Analyte451 ± 50.50656 ± 48.37
BFB-520 Analyte95.7 ± 103.10135 ± 107.95

Adverse events

Collected over Treatment through end of study (Day 17).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Phase 10/17 (0%)1/17 (5.9%)5/17 (29.4%)
Treatment Phase 20/15 (0%)0/15 (0%)5/15 (33.3%)
Most frequent serious events
Most frequent serious events
EventTreatment Phase 1Treatment Phase 2
RhabdomyolysisMusculoskeletal and connective tissue disorders1/170/15
Most frequent other events
Most frequent other events
EventTreatment Phase 1Treatment Phase 2
DizzinessNervous system disorders0/173/15
SomnolenceNervous system disorders0/172/15
HeadacheNervous system disorders2/170/15
SyncopeNervous system disorders0/171/15
Electrocardiogram T wave inversionInvestigations0/171/15
PresyncopeNervous system disorders1/170/15
Alanine aminotransferase increasedInvestigations1/170/15
Blood creatine phosphokinase increasedInvestigations1/170/15
Heart rate increasedInvestigations1/170/15
AgitationPsychiatric disorders1/170/15

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Overall Safety Set
Mean36.3 ± 8.20
Sex: Female, Male
Sex: Female, Male(Participants)Overall Safety Set
Female2
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Safety Set
Hispanic or Latino5
Not Hispanic or Latino12
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Safety Set
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American8
White8
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Overall Safety Set
United States17
Body Mass Index at Baseline
Body Mass Index at Baseline(kg/m2)Overall Safety Set
Mean27.3 ± 4.58
08

Study locations

3 sites
  • Collaborative Neuroscience Research, LLC
    Garden Grove, California 92845, United States
  • CBH Health, LLC
    Gaithersburg, Maryland 20877, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jan 2024, 2 months.

Results were first posted in Mar 2025, 1 year 2 months after primary completion.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 2 months is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2023
First posted
Oct 30, 2023
StartActual
Oct 13, 2023
Primary completionActual
Jan 12, 2024
CompletionActual
Jan 12, 2024
Results first posted
Mar 26, 2025
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06107803
Lead sponsor
Minerva Neurosciences
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Oct 13, 2023
Primary completion
Jan 12, 2024
Completion
Jan 12, 2024
Results posted
Mar 26, 2025
Last update
Mar 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roluperidone

Start the discussion